PfSPZ-LARC2 Vaccine

BIOLOGICAL3 trials

Sponsors

Sanaria Inc.

Conditions

Malaria (Plasmodium Falciparum)Malaria FalciparumMalaria Infection

Phase 1

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

CompletedNCT06652737

Sanaria Inc.Malaria Falciparum, Malaria Infection

Start: 2025-03-04End: 2026-02-18Updated: 2026-04-16

Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults

RecruitingNCT06862453

Sanaria Inc.Malaria Falciparum

Start: 2026-03-12End: 2026-12-30Target: 58Updated: 2026-06-22

Phase 2

PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali

Not yet recruitingNCT07675785

Sanaria Inc.Malaria (Plasmodium Falciparum)

Start: 2026-07-15End: 2030-04-01Target: 300Updated: 2026-07-08